# An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

> **NCT04671849** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 243 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion

## Interventions

- **DRUG:** SIM1803-1A

## Key facts

- **NCT ID:** NCT04671849
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-21
- **Primary completion:** 2022-09-30
- **Final completion:** 2024-01-30
- **Target enrollment:** 243 (ESTIMATED)
- **Last updated:** 2021-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671849, "An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04671849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*